{
    "score": [
        0.7857142857142857
    ],
    "extracted": [
        0
    ],
    "abstract": [
        "new york state common retirement fund takes $ 830,000 position in astrazeneca plc ."
    ],
    "id": "682761.train",
    "article": [
        "new york state common retirement fund acquired a new stake in astrazeneca plc in the 3rd quarter , according to its most recent form 13f filing with the securities and exchange commission . the fund acquired 24,512 shares of the company 's stock , valued at approximately $ 830,000 . a number of other institutional investors have also recently made changes to their positions in azn . bank of new york mellon corp increased its holdings in astrazeneca by 6.1 % in the second quarter . bank of new york mellon corp now owns 195,965 shares of the company 's stock valued at $ 6,681,000 after buying an additional 11,311 shares during the last quarter . ",
        "neuberger berman group llc grew its holdings in shares of astrazeneca by 0.9 % during the second quarter . neuberger berman group llc now owns 105,111 shares of the company 's stock valued at $ 3,583,000 after purchasing an additional 924 shares during the last quarter . bronfman e. l. rothschild l. p. grew its holdings in shares of astrazeneca by 71.2 % during the second quarter . bronfman e. l. rothschild l. p. now owns 4,252 shares of the company 's stock valued at $ 145,000 after purchasing an additional 1,769 shares during the last quarter . cibc world markets inc. . ",
        "grew its holdings in shares of astrazeneca by 82.2 % during the second quarter . cibc world markets inc. . now owns 102,174 shares of the company 's stock valued at $ 3,483,000 after purchasing an additional 46,110 shares during the last quarter . finally , hpm partners llc grew its holdings in shares of astrazeneca by 20.3 % during the second quarter . hpm partners llc now owns 16,212 shares of the company 's stock valued at $ 714,000 after purchasing an additional 2,732 shares during the last quarter . 14.75 % of the stock is owned by hedge funds and other institutional investors . ",
        "several equities analysts have recently commented on the company . zacks investment research lowered astrazeneca from a `` hold '' rating to a `` sell '' rating in a report on wednesday . citigroup raised astrazeneca to a `` buy '' rating in a report on wednesday , october 18th . cowen reaffirmed a `` hold '' rating and set a $ 37.00 target price on shares of astrazeneca in a report on tuesday , october 17th . leerink swann upped their target price on astrazeneca from $ 31.00 to $ 34.00 and gave the company a `` market perform '' rating in a report on monday , october 23rd . ",
        "finally , credit suisse group raised astrazeneca from a `` neutral '' rating to an `` outperform '' rating in a report on monday , october 16th . four analysts have rated the stock with a sell rating , seven have assigned a hold rating and thirteen have assigned a buy rating to the company . astrazeneca presently has a consensus rating of `` hold '' and an average price target of $ 34.20 . astrazeneca plc opened at $ 35.87 on friday . astrazeneca plc has a fifty-two week low of $ 26.51 and a fifty-two week high of $ 35.92 . ",
        "the stock has a market capitalization of $ 89,390.00 , a p/e ratio of 25.62 , a p/e/g ratio of 3.40 and a beta of 0.76 . the company has a debt-to-equity ratio of 1.09 , a current ratio of 0.94 and a quick ratio of 0.72 . astrazeneca last issued its quarterly earnings data on thursday , november 9th . the company reported $ 1.12 earnings per share for the quarter , topping analysts ' consensus estimates of $ 0.57 by $ 0.55 . astrazeneca had a return on equity of 34.02 % and a net margin of 15.90 % . ",
        "the business had revenue of $ 6.23 billion during the quarter , compared to analyst estimates of $ 6 billion . during the same period in the prior year , the company posted $ 1.32 eps . the business 's revenue for the quarter was up 9.4 % compared to the same quarter last year . analysts anticipate that astrazeneca plc will post 1.88 earnings per share for the current fiscal year . about astrazenecaastrazeneca plc is a biopharmaceutical company . the company focuses on discovery and development of products , which are then manufactured , marketed and sold . ",
        "the company focuses on three main therapy areas : oncology , cardiovascular & metabolic disease and respiratory , while selectively pursuing therapies in autoimmunity , infection and neuroscience .   "
    ]
}